Jefferies Group’s ANI Pharmaceuticals ANIP Stock Holding History

Jefferies Group’s Portfolio ANIP Stock Details ANIP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-24,200	Closed	-$1.5M	–	2261
2015 Q2	$1.5M	Buy	+24,200	New	+$1.44M	0.01%	1061

Other funds holding ANIP

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return

Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Jefferies Group's ANIP Position: Q2 2018 in Review

Jefferies Group sold out of ANI Pharmaceuticals (ANIP) in Q2 2018, closing a stake of 29,244 shares — an estimated $1.7M sold.

Jefferies Group first reported a position in ANIP in Q2 2015 and held it in 3 quarters. The position peaked at $1.7M in Q1 2018. 184 funds tracked by Wall St. Rank hold ANIP as of Q2 2018.

Jefferies Group reported no remaining ANI Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
Jefferies Group sold 29,244 ANI Pharmaceuticals shares in Q2 2018, an estimated $1.7M.
Jefferies Group first reported a position in ANI Pharmaceuticals in Q2 2015 and held it in 3 quarters.
Jefferies Group's ANI Pharmaceuticals position peaked at $1.7M in Q1 2018.
184 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2018.

Based on Jefferies Group's 13F filing for Q2 2018, filed 14 Aug 2018.